Final data from a randomized, double-blind study of the Revian Red hair growth system demonstrated the ability of the system to successfully stop hair loss and subsequently grow new hair. Findings were presented at the 2020 Winter Clinical Dermatology Conference – Hawaii and are now available on the Revian website.

Adult men and women diagnosed with androgenetic alopecia were randomly assigned to use of the Revian Red dual wavelength, all-LED hair growth cap or placebo cap (with no light therapy) for 10 minutes per day. Among participants who were at least 80 percent compliant with the treatment protocol, use of the Revian Red system was associated with a mean improvement of 26.3 hairs/cm² over the placebo cap. Preliminary results had shown that participants assigned Revian Red had an average of 21.3 more hairs/cm². 

As part of the study, a quality-of-life questionnaire was used to assess itching, burning and stinging, irritation, and other patient-reported outcomes. Participants scored each question on a scale from 1 (never) to 5 (all the time). Statistically significant reductions were observed in patient-reported pruritus (itch) and burning/stinging compared to sham after 16 weeks of once-daily, at-home treatment. 

“Scalp symptoms such as pruritus, burning, and irritation are extremely common complaints in the dermatological setting and can be frustrating for both the patient and dermatologist alike,” states Mark S. Nestor, MD, Director of the Center for Clinical and Cosmetic Research and a Voluntary Professor at the Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine. “The clinical data showing significant reduction in itching, burning, and irritation observed with this new class of LED light therapy that utilizes two wavelengths of light is extremely encouraging.”

The mechanisms of action for improved scalp symptoms are proposed to be the anti-inflammatory effects of nitric oxide (NO) released with the patented dual wavelength light. Revian, Inc. is unaware of any previous reports of a reduction in “itchy scalp” with traditional single-color laser-based devices used to treat androgenetic alopecia. 

The dual wavelength, all-LED Revian Red device demonstrated excellent safety. During the trial, there were no treatment discontinuations due to an adverse event and there were no device-related serious adverse events reported for any treatment arm.